We have located links that may give you full text access.
Journal Article
Research Support, Non-U.S. Gov't
Review
What do we know about duloxetine's mode of action? Evidence from animals to humans.
The serotonin (5-hydroxytryptamine [5-HT]) and noradrenalin (NA) reuptake inhibitor duloxetine is currently the only widely approved pharmacological treatment option for women with stress urinary incontinence (SUI). The rationale for employing duloxetine in SUI is based on the role of 5-HT and NA in the neurological control of the lower urinary tract. Animal studies have shown that duloxetine increases the concentration of 5-HT and NA in the sacral spinal cord, thereby facilitating an increased activity of the external urethral sphincter (rhabdosphincter) and preventing urine leakage during the storage phase of the micturition cycle. Importantly, 5-HT and NA exert only a modulatory effect as they are not able to directly excite motor neurons. Glutamate is the key descending neurotransmitter and can be considered as the "on/off" switch for micturition. In the absence of glutamate, no rhabdosphincter activity is observed, irrespective of the presence of 5-HT and NA. Hence, duloxetine enhances sphincter activity during urine storage when glutamate is released but allows complete relaxation of the rhabdosphincter once glutamate release is inhibited during the voiding phase. The efficacy of duloxetine for treating women with SUI, as shown in several double-blind, placebo-controlled randomised clinical trials, has suggested a similar mode of action, although no direct evidence for this pathway in humans was available until recently. Two recent studies provide support for duloxetine's mechanism of action in humans. Duloxetine was shown to have a significant effect on the excitability of pudendal motor neurons and on sphincter contractility in healthy women. In contrast, no relevant effect was observed on urethral resting tone. Another study reported important increases in Valsalva leak point pressure and in the rhabdosphincter electrical activity at rest and with coughing in women with SUI who responded to duloxetine. These studies support the hypothesis that duloxetine in women with SUI enhances urethral closure through neuromodulation of the rhabdosphincter.
Full text links
Related Resources
Trending Papers
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities.Diabetologia 2024 April 17
British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease.Rheumatology 2024 April 17
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Albumin: a comprehensive review and practical guideline for clinical use.European Journal of Clinical Pharmacology 2024 April 13
Eosinophilic Esophagitis: Clinical Pearls for Primary Care Providers and Gastroenterologists.Mayo Clinic Proceedings 2024 April
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app